Abstract
Human genetics research employs the two opposing approaches of forward and reverse genetics. While forward genetics identifies and links a mutation to an observed disease etiology, reverse genetics induces mutations in model organisms to study their role in disease. In most cases, causality for mutations identified by forward genetics is confirmed by reverse genetics through the development of genetically engineered animal models and an assessment of whether the model can recapitulate the disease. While many technological advances have helped improve these approaches, some gaps still remain. CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated), which has emerged as a revolutionary genetic engineering tool, holds great promise for closing such gaps. By combining the benefits of forward and reverse genetics, it has dramatically expedited human genetics research. We provide a perspective on the power of CRISPR-based forward and reverse genetics tools in human genetics and discuss its applications using some disease examples.
Similar content being viewed by others
References
Aida T, Chiyo K, Usami T, Ishikubo H, Imahashi R, Wada Y, Tanaka KF, Sakuma T, Yamamoto T, Tanaka K (2015) Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. Genome Biol. doi:10.1186/s13059-015-0653-x
Angeli S, Lin X, Liu XZ (2012) Genetics of hearing and deafness. Anat Rec Adv Integr Anat Evol Biol 295:1812–1829. doi:10.1002/ar.22579
Bedell MA, Jenkins NA, Copeland NG (1997) Mouse models of human disease. Part I: techniques and resources for genetic analysis in mice. Genes Dev 11:1–10
Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, Scott DA, Song J, Pan JQ, Weissleder R, Lee H, Zhang F, Sharp PA (2015) Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160:1246–1260. doi:10.1016/j.cell.2015.02.038
Chen Z-Y, Tao Y, Gao X, Hu Y, Dai P, Kong W, Liu D (2016) Restoration of hearing by CRISPR/Cas9-mediated genome editing in the Pmca2 deafness mouse model by protein delivery. Assoc Res Otolaryngol Abs 39:138–139
Chiou S-H, Winters IP, Wang J, Naranjo S, Dudgeon C, Tamburini FB, Brady JJ, Yang D, Grüner BM, Chuang C-H, Caswell DR, Zeng H, Chu P, Kim GE, Carpizo DR, Kim SK, Winslow MM (2015) Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev 29:1576–1585. doi:10.1101/gad.264861.115
Claussnitzer M, Dankel SN, Kim K-H, Quon G, Meuleman W, Haugen C, Glunk V, Sousa IS, Beaudry JL, Puviindran V, Abdennur NA, Liu J, Svensson P-A, Hsu Y-H, Drucker DJ, Mellgren G, Hui C-C, Hauner H, Kellis M (2015) FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med 373:895–907. doi:10.1056/NEJMoa1502214
Dow LE, Fisher J, O’Rourke KP, Muley A, Kastenhuber ER, Livshits G, Tschaharganeh DF, Socci ND, Lowe SW (2015) Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 33:390–394. doi:10.1038/nbt.3155
Fujii W, Kawasaki K, Sugiura K, Naito K (2013) Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease. Nucleic Acids Res 41:e187–e187. doi:10.1093/nar/gkt772
Grati M, Yan D, Raval MH, Walsh T, Ma Q, Chakchouk I, Kannan-Sundhari A, Mittal R, Masmoudi S, Blanton SH, Tekin M, King M-C, Yengo CM, Liu XZ (2016) Myo3a causes human dominant deafness and interacts with protocadherin 15-Cd2 isoform. Hum Mutat. doi:10.1002/humu.22961
Gurumurthy CB, Quadros R, Sato M, Mashimo T, Lloyd KCK, Ohtsuka M (2016) CRISPR/Cas9 and the paradigm shift in mouse genome manipulation technologies. In: Turksen K (ed) Genome editing. doi:10.1007/978-3-319-34148-4
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Harms DW, Quadros RM, Seruggia D, Ohtsuka M, Takahashi G, Montoliu L, Gurumurthy CB (2014) Mouse genome editing using the CRISPR/Cas system. Curr Protoc Hum Genet Editor Board Jonathan Haines Al 83:15.7.1–15.7.27. doi:10.1002/0471142905.hg1507s83
Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL (2014) Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32:941–946. doi:10.1038/nbt.2951
Jiang J, Zhang L, Zhou X, Chen X, Huang G, Li F, Wang R, Wu N, Yan Y, Tong C, Srivastava S, Wang Y, Liu H, Ying Q-L (2016) Induction of site-specific chromosomal translocations in embryonic stem cells by CRISPR/Cas9. Sci Rep 6:21918. doi:10.1038/srep21918
Kim H, Kim J-S (2014) A guide to genome engineering with programmable nucleases. Nat Rev Genet 15:321–334. doi:10.1038/nrg3686
Kim D, Bae S, Park J, Kim E, Kim S, Yu HR, Hwang J, Kim J-I, Kim J-S (2015) Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods 12:237–243. doi:10.1038/nmeth.3284
Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK (2016) High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490–495. doi:10.1038/nature16526
Lin S, Staahl BT, Alla RK, Doudna JA (2014) Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife. doi:10.7554/eLife.04766
Liu XZ, Yan D (2007) Ageing and hearing loss. J Pathol 211:188–197. doi:10.1002/path.2102
Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2000) Mutations: types and causes. In: Molecular cell biology, 4th edn. W H Freeman, New York
Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han Y-C, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516:423–427. doi:10.1038/nature13902
Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL (2015) Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33:538–542. doi:10.1038/nbt.3190
Mianné J, Chessum L, Kumar S, Aguilar C, Codner G, Hutchison M, Parker A, Mallon A-M, Wells S, Simon MM, Teboul L, Brown SDM, Bowl MR (2016) Correction of the auditory phenotype in C57BL/6N mice via CRISPR/Cas9-mediated homology directed repair. Genome Med. doi:10.1186/s13073-016-0273-4
Miura H, Gurumurthy CB, Sato T, Sato M, Ohtsuka M (2015) CRISPR/Cas9-based generation of knockdown mice by intronic insertion of artificial microRNA using longer single-stranded DNA. Sci Rep 5:12799. doi:10.1038/srep12799
Moresco EMY, Li X, Beutler B (2013) Going forward with genetics. Am J Pathol 182:1462–1473. doi:10.1016/j.ajpath.2013.02.002
Morton CC, Nance WE (2006) Newborn hearing screening—a silent revolution. N Engl J Med 354:2151–2164. doi:10.1056/NEJMra050700
Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351:403–407. doi:10.1126/science.aad5143
Orack JC, Deleidi M, Pitt D, Mahajan K, Nicholas JA, Boster AL, Racke MK, Comabella M, Watanabe F, Imitola J (2015) Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. Stem Cells Transl Med 4:252–260. doi:10.5966/sctm.2014-0133
Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F (2014) CRISPR-Cas9 Knockin mice for genome editing and cancer modeling. Cell 159:440–455. doi:10.1016/j.cell.2014.09.014
Sánchez-Rivera FJ, Jacks T (2015) Applications of the CRISPR–Cas9 system in cancer biology. Nat Rev Cancer 15:387–395. doi:10.1038/nrc3950
Savić N, Schwank G (2016) Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res 168:15–21. doi:10.1016/j.trsl.2015.09.008
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84–87. doi:10.1126/science.1247005
Shalem O, Sanjana NE, Zhang F (2015) High-throughput functional genomics using CRISPR–Cas9. Nat Rev Genet 16:299–311. doi:10.1038/nrg3899
Shen B, Zhang J, Wu H, Wang J, Ma K., Li Z, Zhang X, Zhang P, Huang X (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23:720–723. doi:10.1038/cr.2013.46
Shmakov S, Abudayyeh OO, Makarova KS, Wolf YI, Gootenberg JS, Semenova E, Minakhin L, Joung J, Konermann S, Severinov K, Zhang F, Koonin EV (2015) Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol Cell 60:385–397. doi:10.1016/j.molcel.2015.10.008
Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351:84–88. doi:10.1126/science.aad5227
Spiden SL, Bortolozzi M, Di Leva F, de Angelis MH, Fuchs H, Lim D, Ortolano S, Ingham NJ, Brini M, Carafoli E, Mammano F, Steel KP (2008) The novel mouse mutation Oblivion inactivates the PMCA2 pump and causes progressive hearing loss. PLoS Genet 4:e1000238. doi:10.1371/journal.pgen.1000238
Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, Wyvekens N, Khayter C, Iafrate AJ, Le LP, Aryee MJ, Joung JK (2014) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33:187–197. doi:10.1038/nbt.3117
Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153:910–918. doi:10.1016/j.cell.2013.04.025
Wang T, Wei JJ, Sabatini DM, Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343:80–84. doi:10.1126/science.1246981
Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T (2014) CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514:380–384. doi:10.1038/nature13589
Yan D, Liu X-Z (2010) Modifiers of hearing impairment in humans and mice. Curr Genom 11:269–278. doi:10.2174/138920210791233054
Yan J, Enge M, Whitington T, Dave K, Liu J, Sur I, Schmierer B, Jolma A, Kivioja T, Taipale M, Taipale J (2013) Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell 154:801–813. doi:10.1016/j.cell.2013.07.034
Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, Yu H, Xu C, Morizono H, Musunuru K, Batshaw ML, Wilson JM (2016) A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 34:334–338. doi:10.1038/nbt.3469
Yin H, Song C-Q, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S, Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA, Langer R, Xue W, Anderson DG (2016) Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 34:328–333. doi:10.1038/nbt.3471
Yoshimi K, Kunihiro Y, Kaneko T, Nagahora H, Voigt B, Mashimo T (2016) ssODN-mediated knock-in with CRISPR-Cas for large genomic regions in zygotes. Nat Commun 7:10431. doi:10.1038/ncomms10431
Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F (2015) Cpf1 Is a single rna-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163:759–771. doi:10.1016/j.cell.2015.09.038
Zhang L, Jia R, Palange NJ, Satheka AC, Togo J, An Y, Humphrey M, Ban L, Ji Y, Jin H, Feng X, Zheng Y (2015) Large genomic fragment deletions and insertions in mouse using CRISPR/Cas9. PLoS One 10:e0120396. doi:10.1371/journal.pone.0120396
Zhou Y, Zhu S, Cai C, Yuan P, Li C, Huang Y, Wei W (2014) High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509:487–491. doi:10.1038/nature13166
Zou B, Mittal R, Grati M, Lu Z, Shu Y, Tao Y, Feng Y, Xie D, Kong W, Yang S, Chen Z-Y, Liu X (2015) The application of genome editing in studying hearing loss. Hear Res 327:102–108. doi:10.1016/j.heares.2015.04.016
Zuckermann M, Hovestadt V, Knobbe-Thomsen CB, Zapatka M, Northcott PA, Schramm K, Belic J, Jones DTW, Tschida B, Moriarity B, Largaespada D, Roussel MF, Korshunov A, Reifenberger G, Pfister SM, Lichter P, Kawauchi D, Gronych J (2015) Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat Commun 6:7391. doi:10.1038/ncomms8391
Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, Maeder ML, Joung JK, Chen Z-Y, Liu DR (2014) Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33:73–80. doi:10.1038/nbt.3081
Acknowledgments
We thank Sidi Chen for his helpful comments on the manuscript. CBG’s lab is partially supported by National Institute of General Medical Sciences of the National Institutes of Health under Grant No. P20GM103471 and the Center for Humanized Mice from ORIP/DPCPSI/NIH/1R24OD018546-01. XZL’s lab is supported by R01 DC05575, R01 DC01246, and R01 DC012115 from the National Institutes of Health/National Institute on Deafness and Other Communication Disorders. SLPS is supported by the NSF Graduate Research Fellowship DGE1144152. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation. We apologize to colleagues whose studies could not be cited because of space constraints.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Gurumurthy, C.B., Grati, M., Ohtsuka, M. et al. CRISPR: a versatile tool for both forward and reverse genetics research. Hum Genet 135, 971–976 (2016). https://doi.org/10.1007/s00439-016-1704-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-016-1704-4